Stocks
Apimeds Pharmaceuticals US, Inc.APUS
AMEXHealthcareBiotechnology$2.89
Price as of · delayed, not real-time
A biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders, including treatments for epilepsy and other neurological conditions. Its lead product candidate targets a niche within the neurology market, and investors track the company for its clinical-stage pipeline and potential regulatory milestones.
52W Range: $1.51-$59.70
Congressional Interest in Apimeds Pharmaceuticals US, Inc. (APUS)
No congressional trades have been disclosed for Apimeds Pharmaceuticals US, Inc. (APUS) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading APUS?
No congressional trades found for this stock.